Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Melrose Industries rallies as Citi remains 'high conviction' in the buy case

(Sharecast News) - Melrose Industries shot higher on Tuesday as Citi said it remains "high conviction" in the 'buy' case, given the trough multiple and the strong mid-term cash outlook.

The bank said mid-term cash generation is a central question for investors.

"The growth in receivables, driven by 'pull forward' revenue recognition from the RRSP portfolio, is key to understanding the relationship between profit and cash," it said.

"In this report, we utilise some of the information from the RRSP explainer to drive our receivables estimates."

Citi said that from its analysis, it concludes the company could be generating about £450m to £550m free cash flow in the 2027/2028 timeframe, versus VA consensus of £320m to £420m.

"On peer free cash flow yields, this gives a valuation of £6-8, i.e 30% upside at the low end," it said.

At 1510 GMT, the shares were up 3.9% at 492.62p.

Shares in Melrose surged last Monday after it released a document explaining the accounting around its 19 Risk and Revenue Sharing Partnerships (RRSPs) and said the portfolio was "well positioned" to generate significant returns for investors in the coming decades.

Share this article

Related Sharecast Articles

Sabien Technology inks invoice facility with chairman's firm
(Sharecast News) - Sabien Technology Group announced on Monday that it would enter into an invoice factoring facility with Parris Group, the family office of its executive chairman Richard Parris, to provide additional working capital as it expanded sales of its M2G Cloud Connect service.
CleanTech reports 17pc increase in Laguna Verde resource estimate
(Sharecast News) - CleanTech Lithium reported a 17% increase in the mineral resource estimate for its Laguna Verde project in Chile on Monday, following the acquisition of additional licences, positioning the asset among the country's key lithium developments earmarked for accelerated private-sector advancement.
Abingdon Health secures $2m contract with US-based client
(Sharecast News) - Abingdon Health announced on Monday that it has secured a contract worth about $2m to develop and scale up a new multiplex lateral flow diagnostic test for a US-based client.
Metsera agrees $10bn takeover by Pfizer, shares slide
(Sharecast News) - US biotech firm Metsera tumbled on Monday after it agreed to be bought by Pfizer in a sweetened $10bn deal, with Denmark's Novo Nordisk refraining from making an increased offer.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.